Grifols stock climbs as half-year profit rises 28.7%
Published on 08/19/2026 at 19:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Grifols stock is drawing attention after first-half 2026 net profit rose 28.7% to €227 million, with revenue at €3.574 billion and adjusted EBITDA at €854 million. The shares were last quoted at EUR 7.070 on August 19, 2026, after a 1.87% move in the session.
Half-year numbers set the tone
The latest reported period was the first half of 2026, when revenue climbed 2.6% at constant currency to €3.574 billion and biopharma revenue rose 5.4%. Immunoglobulin sales increased 12.8% in that period, while intravenous formulations rose 12.5% and subcutaneous products gained 17.7%.
Adjusted EBITDA reached €854 million, which translated into a 23.9% margin, and that combination of margin and profit growth is more useful for investors than the revenue line alone. The comparison with the first half of 2025 is clean: profit expanded 28.7% while the business kept margin above 20%.
Market tone stays supportive
MarketScreener showed Grifols at EUR 7.070 at 10:30:02 a.m. EDT on August 19, 2026, with the stock up 1.87% over five days and flat year to date in the quoted snapshot. That puts the shares in a narrow trading range after a strong first-half report, with the market still weighing cash generation against the pace of operating recovery.
MarketBeat's stock page showed a prior close of $7.75 on August 18, 2026, with extended trading at $7.72. Its forecast page also described the analyst view as a reduce call, which keeps expectations cautious even after the latest results.
Prolastin-C remains visible
Grifols' own products still matter to the story, especially Prolastin-C, a therapy used in emphysema related to alpha-1 antitrypsin deficiency. The company said on August 10, 2026, that it completed the clinical portion of the Phase 3 trial of Prolastin-C in emphysema, a development that adds another evidence point to the product pipeline.
For investors, the mix is straightforward: a €227 million half-year profit, €854 million of adjusted EBITDA, and a stock that was last quoted at EUR 7.070 on August 19, 2026. The market is now judging whether the improved 2026 operating picture can hold.
More on Grifols stock
Grifols is a Spanish plasma-derived medicines and diagnostics company with biopharma, diagnostics, biosupplies and bio supplies-related activities. Prolastin-C is one of the group's best-known therapies and remains tied to the company's long-running plasma medicine franchise.
Share level and valuation
As of August 19, 2026, Grifols stock was quoted at EUR 7.070 on MarketScreener's real-time valuation page. The same page showed a five-day change of 1.87% and a year-to-date change of 0.00%.
Company facts
Company: Grifols, S.A.
ISIN: ES0171996087
Ticker: GRFS
Exchange: OTC
Sector / Industry: Health Care / Biotechnology
Index membership: Ibex 35
